CurrentBlue Cross Blue Shield - TexasPolicy CPCPLABO36

Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases

This clinical payment and coding policy defines reimbursement criteria for serum and cerebrospinal fluid biomarker testing used in the diagnosis of multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD), and MOG-associated encephalomyelitis (MOG-EM) and applies to providers submitting claims to Blue Cross and Blue Shield of Texas.

Policy Summary

PayerBlue Cross Blue Shield - Texas

PolicyBiomarker Testing for Multiple Sclerosis and Related Neurologic Diseases

Policy CodePolicy CPCPLABO36

Change TypeLiterature reviewreimbursement criteria unchanged

Effective DateSep 26, 2025

Next Review Date

Key ActionSubmit accurate documentation and coding; claims are subject to review and plan documents govern coverage.

SourceLink

POLICY UPDATE CHANGES

Title changed from 'Serum Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases' and references were revised; reimbursement information unchanged.

Procedure codes 83884 and 0443U were added to the policy's code list in a prior update.

3CSF oligoclonal band reimbursable situations

multipleClinical features supporting serum testing

1Listed specific codes

policy literature reviews

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Reimbursement Criteria

Reimbursement criteria — Situations where testing may be reimbursable

Situations where testing may be reimbursable:

ALL of the following

May be reimbursable when any of the following are present:
- Atypical clinical, laboratory, or imaging features
- Belonging to a population in which MS is less common (e.g., children, older individuals)
- Atypical clinically isolated syndrome (including but not limited to primary progressive MS or atypical relapsing course)
- Insufficient clinical or imaging evidence for diagnosis

ALL of the following

Testing method: serum indirect fluorescence assay or FACS assay of AQP4-IgG and MOG-IgG
Clinical presentation of monophasic or relapsing acute optic neuritis, myelitis, brainstem encephalitis, encephalitis, or any combination thereof
Radiological or electrophysiological findings compatible with central nervous system (CNS) demyelination
And at least one supportive feature:
- Belongs to a higher-risk population (e.g., pediatric)
- Abnormal MRI depicting extensive optic nerve lesion, extensive cord lesion or atrophy, or large confluent T2 brain lesions

ALL of the following

Any other serum biomarker tests for MS are not reimbursable
ELISA, Western blot, immunohistochemistry, or any other serum assays to test for NMOSD or MOG-EM are not reimbursable
All other CSF biomarker tests, including AQP4-IgG or MOG-IgG, are not reimbursable

Procedure Codes and Coding Notes

Listed procedure codes (not exhaustive)CPT | HCPCS

0443U

Test code listed in policy

Coding inclusion note

Code inclusion noteThe provided code list is not an all-encompassing list; inclusion of a code does not guarantee it is a covered service or eligible for reimbursement.

Example listed code0443U is included in the policy's code list (not exhaustive).

Prior code additionsProcedure codes 83884 and 0443U were added in a prior update (see policy history).

Documentation, Claim Submission, and Payer Discretion

Documentation Required

Documentation and claim submission expectations

Providers are responsible for submission of accurate documentation of services and code combinations from HIPAA‑approved code sets and must code claims according to industry standard coding guidelines (for example, Uniform Billing Editor, AMA CPT, HCPCS, ICD‑10‑CM/PCS, NDCs, DRG guidelines, CMS NCCI Policy Manual and CCI edits). Claims are subject to code edit protocols and claim review, and providers may be asked to submit additional documentation upon request.

Submit accurate documentation and code combinations from HIPAA‑approved code sets.
Code claims per industry standard coding guidelines (CPT, HCPCS, ICD‑10, NCCI, etc.).
Be prepared for claim review and to provide additional documentation upon request.

Note

Payer discretion and governing documents

Blue Cross and Blue Shield of Texas may use reasonable discretion in interpreting and applying this policy to services in a particular case; when conflicts exist, plan documents or provider contracts govern coverage and application.

Test Definitions

Oligoclonal band analysis (CSF and serum)

Test descriptionOligoclonal band analysis (CSF and serum) is testing performed to aid diagnosis of multiple sclerosis (MS).

When reimbursable (high-level)May be reimbursable for MS when individuals have atypical clinical, laboratory, or imaging features; belong to populations where MS is less common (e.g., children, older individuals); present with atypical clinically isolated syndrome (including primary progressive MS or atypical relapsing course); or have insufficient clinical or imaging evidence for diagnosis.

Not reimbursable scopeAll other CSF biomarker tests for MS (including CSF AQP4-IgG or MOG-IgG) are not reimbursable except as specified above.

AQP4-IgG and MOG-IgG serum testing

Assays describedSerum indirect fluorescence assay or fluorescence-activated cell sorting (FACS) assay of AQP4-IgG and MOG-IgG are the testing methods referenced.

Policy Summary

PayerBlue Cross Blue Shield - Texas

PolicyBiomarker Testing for Multiple Sclerosis and Related Neurologic Diseases

Policy CodePolicy CPCPLABO36

Change TypeLiterature reviewreimbursement criteria unchanged

Effective DateSep 26, 2025

Next Review Date

Key ActionSubmit accurate documentation and coding; claims are subject to review and plan documents govern coverage.

SourceLink

On This Page

Prominent papilledema/papillitis/optic disc swelling during acute optic neuritis

Histopathology showing primary demyelination with intralesional complement and IgG deposits or previous diagnosis of pattern II MS

Neutrophilic CSF pleocytosis

Simultaneous bilateral acute optic neuritis

Severe or frequent episodes of acute myelitis or brainstem encephalitis

Severe visual deficit or blindness in one or both eyes during or after acute optic neuritis

Permanent sphincter and/or erectile disorder after myelitis

Previous diagnosis of acute disseminated encephalomyelitis (ADEM)

Plan documents (e.g., Certificates of Benefits, benefit booklets, Summary Plan Descriptions) govern if there is a conflict with this policy.
Provider contract language governs if there is a conflict between the CPCP and a provider contract.

When reimbursable (criteria)

Reimbursable when the individual has monophasic or relapsing acute optic neuritis, myelitis, brainstem encephalitis, encephalitis (or combination), radiological/electrophysiological evidence of CNS demyelination, and at least one supportive feature (e.g., abnormal MRI with extensive optic nerve or cord lesions, belonging to a higher-risk population such as pediatric, prominent papilledema/papillitis, histopathology showing intralesional complement/IgG, neutrophilic CSF pleocytosis, simultaneous bilateral acute optic neuritis, severe/frequent myelitis or brainstem encephalitis, severe visual deficit or blindness, permanent sphincter/erectile disorder after myelitis, or prior ADEM).

Not reimbursable (other methods)ELISA, Western blot, immunohistochemistry, or any other serum assays to test for NMOSD or MOG-EM are not reimbursable.